Adaptive Biotechnologies Corporation (ADPT)
NASDAQ: ADPT · Real-Time Price · USD
14.75
-2.71 (-15.52%)
At close: Dec 5, 2025, 4:00 PM EST
14.79
+0.04 (0.27%)
After-hours: Dec 5, 2025, 7:58 PM EST
Adaptive Biotechnologies Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Adaptive Biotechnologies stock have an average target of 16.6, with a low estimate of 10 and a high estimate of 21. The average target predicts an increase of 12.54% from the current stock price of 14.75.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Adaptive Biotechnologies stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 5 | 5 | 5 |
| Buy | 3 | 3 | 3 | 4 | 4 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $11 → $16 | Hold | Maintains | $11 → $16 | +8.47% | Nov 11, 2025 |
| BTIG | BTIG | Strong Buy Maintains $19 → $21 | Strong Buy | Maintains | $19 → $21 | +42.37% | Nov 6, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $17 → $20 | Buy | Maintains | $17 → $20 | +35.59% | Nov 6, 2025 |
| BTIG | BTIG | Strong Buy Maintains $14 → $19 | Strong Buy | Maintains | $14 → $19 | +28.81% | Oct 22, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $15 → $20 | Buy | Maintains | $15 → $20 | +35.59% | Oct 15, 2025 |
Financial Forecast
Revenue This Year
269.89M
from 178.96M
Increased by 50.81%
Revenue Next Year
273.04M
from 269.89M
Increased by 1.17%
EPS This Year
-0.50
from -1.08
EPS Next Year
-0.59
from -0.50
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 280.1M | 289.3M | |||
| Avg | 269.9M | 273.0M | |||
| Low | 257.7M | 250.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 56.5% | 7.2% | |||
| Avg | 50.8% | 1.2% | |||
| Low | 44.0% | -7.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.48 | -0.54 | |||
| Avg | -0.50 | -0.59 | |||
| Low | -0.50 | -0.64 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.